O0574 Azidothymidine is bactericidal against carbapenem-resistant Enterobacteriaceae and produces synergistic activity in combination with colistin against multidrug-resistant Enterobacteriaceae
Bacterial infections remain the leading killer worldwide which is worsened by the continuous emergence of antibiotic resistance. In particular, antibiotic-resistant Gram-negative bacteria are prevalent and are extremely difficult to treat. Reusing of existing drugs and rejuvenating the therapeutic potential of existing antibiotics represent an attractive novel strategy. Azidothymidine (AZT) is an anti-retroviral drug which is used in combination with other antivirals to prevent and to treat HIV/AIDS. AZT is also active against Gram-negative bacteria but has not been developed for that purpose. Here we investigated the efficacy of AZT against a variety of antibiotic resistant Enterobacteriaceae. We also tested the ability of AZT to enhance the potency of currently used antibiotics particularly colistin against antibiotic-resistant including NDM-1 Enterobacteriaceae.
Click here to read the full paper
Helperby Therapeutics announces phase 1 results demonstrating multiple benefits of its unique combination antibiotic therapy
ECCMID Published Papers - Safety & Pharmacokinetics of i.v azidothymidine alone & combined with Colistin